Aravive, Inc.
- Jurisdiction
United States - ISIN
US03890D1081 (ARAV )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Read full profile
Stock price
Fundamentals
- Net revenue
€6.03M - Gross margin
-663.2% - EBIT
-€22.46M - EBIT margin
-372.7% - Net income
-€69.91M - Net margin
-1,160.1%
Statement period: - (published )
Dividends
No dividend payouts